The financials
Bristol Myers Squibb by the numbers
Bristol Myers Squibb (BMY) reported revenue of $13.0B in Q2 2026 (quarter ended June 30, 2026), up 5.7% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $3.32B (26% of revenue). For the full year FY2025, revenue was $48.2B (−0.2% year on year) and net income $7.05B. Its largest product in 2026-Q1 was Eliquis at $4.14B, 34% of the disclosed total, just ahead of Opdivo at 18%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $13.0B | $12.3B | +5.7% |
| Gross profit | $9.25B | $8.90B | +3.9% |
| Operating income | $4.09B | $1.77B | +130% |
| Net income | $3.32B | $1.31B | +153% |
| Diluted EPS | $1.62 | $0.64 | +153% |
| Product | Revenue | Share |
|---|---|---|
| Eliquis | $4.14B | 34% |
| Opdivo | $2.15B | 18% |
| Orencia | $818M | 6.7% |
| Yervoy | $651M | 5.4% |
| Other Growth Brands | $581M | 4.8% |
| Reblozyl | $555M | 4.6% |
| Pomalyst Imnovid | $513M | 4.2% |
| Breyanzi | $411M | 3.4% |
| Revlimid | $349M | 2.9% |
| Alliance And Other | $321M | 2.6% |
| Camzyos | $314M | 2.6% |
| Opdualag | $295M | 2.4% |
| Other | $227M | 1.9% |
| Opdivo Ovantig | $163M | 1.3% |
| Other Legacy Brands | $156M | 1.3% |
| Zeposia | $118M | 1.0% |
| Alliance | $94M | 0.8% |
| Sprycel | $73M | 0.6% |
| Sotyktu | $69M | 0.6% |
| Cobenfy | $56M | 0.5% |
| Abraxane | $50M | 0.4% |
| Krazati | $50M | 0.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $12.13B (-6.5%)
Opdivo Ovantig grew +1711% year on yearRevlimid -63% year on year
Segment Latestquarter on quarteryear on year
- Eliquis$4.14B$4.14BQoQ +10%year on year +16%+10%+16%
- Opdivo$2.15B$2.15BQoQ -15%year on year -5.3%-15%-5.3%
- Orencia$818.0M$818.0MQoQ -15%year on year +6.2%-15%+6.2%
- Yervoy$651.0M$651.0MQoQ -12%year on year +4.3%-12%+4.3%
- Other Growth Brands$581.0M$581.0MQoQ +13%year on year +15%+13%+15%
- Reblozyl$555.0M$555.0MQoQ -9.8%year on year +16%-9.8%+16%
- Pomalyst Imnovid$513.0M$513.0MQoQ -24%year on year -22%-24%-22%
- Breyanzi$411.0M$411.0MQoQ +14%year on year +56%+14%+56%
- Revlimid$349.0M$349.0MQoQ -39%year on year -63%-39%-63%
- Alliance And Other$321.0M$321.0MQoQ -year on year +1.9%-+1.9%
- Camzyos$314.0M$314.0MQoQ +6.1%year on year +97%+6.1%+97%
- Opdualag$295.0M$295.0MQoQ -1.3%year on year +17%-1.3%+17%
- Other$227.0M$227.0MQoQ -8.1%year on year 0.00%-8.1%0.00%
- Opdivo Ovantig$163.0M$163.0MQoQ +143%year on year +1711%+143%+1711%
- Other Legacy Brands$156.0M$156.0MQoQ -12%year on year -22%-12%-22%
- Zeposia$118.0M$118.0MQoQ -27%year on year +10%-27%+10%
- Alliance$94.0M$94.0MQoQ -25%year on year +6.8%-25%+6.8%
- Sprycel$73.0M$73.0MQoQ -39%year on year -58%-39%-58%
- Sotyktu$69.0M$69.0MQoQ -14%year on year +25%-14%+25%
- Cobenfy$56.0M$56.0MQoQ +30%year on year +107%+30%+107%
- Abraxane$50.0M$50.0MQoQ -32%year on year -52%-32%-52%
- Krazati$50.0M$50.0MQoQ -5.7%year on year +4.2%-5.7%+4.2%
- Abecma--QoQ -year on year ---
- Allianceandotherrevenues--QoQ -year on year ---
- Other Revenue Hedging Activities−$15.0M−$15.0MQoQ -year on year ---
Drug Manufacturers - General
Ranks #7 of 16 by Smart Score